New Stock News | Frontera Therapeutics has submitted its application to the Hong Kong Stock Exchange again, deepening its focus on rAAV ophthalmic gene therapy.

According to the Hong Kong Stock Exchange's disclosure on August 28, Frontera Therapeutics (referred to as "Frontera") has submitted a listing application to the main board of the Hong Kong Stock Exchange, with UBS Group and HAITONG INT'L as its joint sponsors. The company initially submitted its application on December 23, 2025. Company Introduction According to its prospectus, the company was established in 2019 and is a clinical-stage gene therapy company dedicated to the independent development of recombinant adeno-associated virus (rAAV) gene therapies. Frontera's pipeline particularly focuses on ophthalmic and cardiovascular diseases. As of the latest feasible date, the company's product pipeline includes six self-developed rAAV gene therapy candidates, including (i) two core products, FT-002 (a candidate under investigation for the treatment of X-linked Retinitis Pigmentosa ("XLRP")) and FT-003 (a candidate under investigation for treating Neovascular Age-related Macular Degeneration ("nAMD") and Diabetic Macular Edema ("DME") via intravitreal injection); (ii) one key product, FT-001 (a gene therapy candidate for treating Inherited Retinal Disease ("IRD") caused by bi-allelic mutations in the RPE65 gene ("RPE65-related IRD")); and (iii) three additional gene therapy candidates in preclinical and early stages for treating ophthalmic and cardiovascular diseases. The figure below shows the gene therapy drug pipeline under development by the company: Frontera Therapeutics states that its competitive advantages include: a differentiated gene therapy pipeline with leading clinical progress in China; AAVANCE, the company's Bac/Sf9 production platform that enables safe, scalable, and cost-effective high-quality production; leveraging the company's strengths in China and the U.S. to possess strong translational medicine and clinical operational capabilities; EXACTE, the companys rAAV gene therapy R&D platform that supports globally IP-protected product development; and extensive gene therapy expertise across research, translation, clinical, and manufacturing disciplines. Frontera Therapeutics has established an internal R&D team consisting of 37 members as of June 30, 2026, with a presence in China and the U.S., of which over 56% hold doctoral or master's degrees, primarily in medicine, biology, pharmacology, chemistry, and other relevant fields. The average industry experience of the R&D team exceeds ten years, and its members possess strong scientific talent and extensive experience in multinational pharmaceutical companies. Notably, the company's research leadership team has significant previous experience in gene therapy research and a proven track record in advancing gene therapy product development. As of the latest feasible date, Frontera Therapeutics has not obtained market approval for any of its candidates and has not generated any revenue from product sales. Financial Information R&D Expenditure For the years ending December 31, 2024, and December 31, 2025, the company's R&D expenditures were $20.6 million and $13.9 million, accounting for 74.6% and 73.1% of the company's total operating expenses (defined as the sum of R&D expenditures and general and administrative expenses for the respective years). For the six months ending June 30, 2025, and June 30, 2026, the company's R&D expenditures were $7.1 million and $5.3 million, accounting for 72.4% and 68.6% of total operating expenses, respectively. For the years ending December 31, 2024, and December 31, 2025, and for the six months ending June 30, 2026, the R&D expenditures incurred in the U.S. were $8.4 million, $5.1 million, and $1.1 million, collectively accounting for 36.5% of the company's total R&D expenditures during the reporting periods. Losses for the Year/Period For the years ending December 31, 2024, and December 31, 2025, the company recorded net losses of $26.5 million and $19.5 million, while for the six months ending June 30, 2025, and June 30, 2026, the net losses were $8.2 million and $4.7 million, respectively. The change in net losses was mainly due to a reduction in R&D expenditures. Industry Overview The global gene therapy market has experienced rapid growth over the past few years, reaching a market size of $3.6 billion by 2025. From 2020 to 2025, the market is undergoing an exponential growth phase with a compound annual growth rate (CAGR) of 226.6%. Looking ahead, the global market is projected to grow at a CAGR of 28.1% from 2025 to 2030, reaching a market size of $12.5 billion by 2030. The market is expected to increase further to $32 billion by 2035, with a CAGR of 20.8% from 2030 to 2035. By 2025, the gene therapy market in China is still in its very early stages, with a total market size of approximately RMB 40 million. The market is anticipated to grow at a CAGR of 143.8% from 2025 to 2030, reaching a market size of RMB 3.2 billion by 2030. This market is expected to further expand to RMB 22.8 billion by 2035, with a CAGR of 90.1% from 2030 to 2035. AAV is a single-stranded DNA virus, with inverted terminal repeat ("ITR") sequences at both ends of its genomic DNA, which are necessary for the initiation of DNA replication and packaging of recombinant AAV virus particles. Between the ITR sequences lies the viral coding region, which contains two genes, Rep and Cap. The Rep gene is primarily responsible for the replication of the viral genome and its integration with the host genome, while the Cap gene is mainly responsible for the packaging of the viral genome and its secretion from host cells. As of the latest feasible date, there are over 250 rAAV gene therapy products in development, with five in the BLA stage. Development remains focused on early clinical exploration: approximately 53% are in Phase I/II trials to verify safety, preliminary efficacy, and dose exploration. Independent Phase I studies account for an additional 27%, reflecting a steady influx of first-in-human trial candidates. Later-stage activities are emerging but remain modest Phase III projects account for 10% of the pipeline, Phase II accounts for 6%, and Phase II/III accounts for 3%. Rare diseases and ophthalmic disorders account for the majority of the global rAAV gene therapy pipeline. Treatments for rare diseases comprise over half of all rAAV gene therapy products in development. Additionally, in terms of therapeutic domains, ophthalmic diseases are the primary targeted area, with other promising fields including neuromuscular, cardiovascular, and hematological diseases. In recent years, rAAV gene therapy has emerged as a promising treatment option for several ophthalmic diseases, particularly retinal neovascular diseases. Compared to other treatment options, rAAV gene therapy offers several key advantages that allow it to meet existing unmet medical needs. The global ophthalmic pharmaceuticals market has maintained steady growth over the past five years, increasing from $33.5 billion in 2020 to $44.1 billion in 2025, with a CAGR of 5.7%. The global ophthalmic pharmaceuticals market is expected to approach $49.4 billion by 2030 and reach $65.5 billion by 2035, with a CAGR of 2.3% from 2025 to 2030 and a CAGR of 5.8% from 2030 to 2035. Currently, there are no approved rAAV-based gene therapy products for indications that are the same as the company's core products. Board Information The board of Frontera Therapeutics consists of nine directors, including one executive director, five non-executive directors, and three independent non-executive directors. According to the articles of association, directors serve a term of three years and are eligible for reelection. The board of the company is responsible for and has general authority to manage and handle the company's business. Equity Structure As of the latest feasible date, the general partner of OrbiMed Asia Partners III, L.P. ("OrbiMed Asia") is OrbiMed Asia GP III, L.P., while OrbiMed Advisors III Limited is its general partner. As of the latest feasible date, the general partner of OrbiMed Private Investments VII, LP ("OrbiMed U.S.") is OrbiMed Capital GP VII LLC, and OrbiMed Advisors LLC is its managing member. OrbiMed Advisors LLC serves as the consulting company for OrbiMed Asia and enjoys voting rights according to its consulting agreement with OrbiMed Asia. OrbiMed Advisors LLC also holds controlling voting rights over OrbiMed U.S. Therefore, OrbiMed Asia and OrbiMed U.S. are jointly controlled by OrbiMed Advisors LLC. Intermediary Team Joint Sponsors: UBS Securities Hong Kong Limited, HAITONG INT'L Capital Limited Company Legal Advisors: Sidley Austin LLP and its affiliates, Wilmer Cutler Pickering Hale and Dorr LLP, Zhong Lun Law Firm, and Haynes and Boone LLP Joint Sponsor Legal Advisors: Skadden, Arps, Slate, Meagher & Flom LLP, and Hogan Lovells Reporting Accountants and Auditors: Deloitte Touche Tohmatsu Certified Public Accountants Industry Advisors: Frost & Sullivan (Beijing) Consulting Co., Ltd. Shanghai Branch